The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study.

Guofeng Chen, Jiaqi Yang,Fuliang Cao,Wei Zhou,Dan Gong,Liren Liu,Dejun Zhou

Annals of translational medicine（2022）

引用 0|浏览7

暂无评分

摘要

IDAC was suitable for patients with additional -X, del(9q), or complex karyotype, while LDAC might be sufficient for patients with t(8;21)-only or additional -Y cytogenetics. It suggested that t(8;21) AML patients with different karyotypes should use different consolidation regimens.

查看译文

关键词

21) acute myeloid leukemia (AML),Cytarabine,consolidation therapy,cytogenetics,t(8

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要